Press Release

CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, is pleased to announce the availability of Polystyrene Family polymers for a variety of drug delivery applications. These polymers offer tunable physicochemical properties that enable sustained release profiles and improved drug bioavailability.

The polystyrene family, a group of polymers derived from the styrene monomer, has attracted considerable interest in the field of drug delivery due to its versatility of properties and applications. Polystyrene consists of both homopolymers and copolymers that offer a wide range of options for customizing drug delivery systems to meet specific therapeutic needs.

CD Bioparticles is committed to providing researchers with the tools they need to develop new and effective drug delivery systems. Recognizing the immense potential of the polystyrene family, CD Bioparticles is expanding its low PDI polymer portfolio to offer a variety of polystyrene family polymers with different molecular weights and surface properties to meet the specific needs of each drug delivery application.

The company's polystyrene family polymers are a versatile platform for the design of drug carriers, offering several advantages. For example, the versatility of polystyrene is demonstrated by its ability to be modified for controlled drug release, bioadhesion and targeted drug delivery. The inert nature of polystyrene enhances drug stability and ensures the integrity of the drug formulation. In addition, polystyrene's compatibility with a wide range of drugs and other materials allows the creation of versatile drug delivery platforms.

Furthermore, the polystyrene family's compatibility with various manufacturing technologies, including micro- and nanoscale technologies, makes it versatile for drug carrier design. The tunable physicochemical properties of polystyrene contribute to its great potential for sustained release and improved drug bioavailability.

In the evolving field of drug delivery, the polystyrene family offers a promising avenue for researchers and pharmaceutical developers, providing a platform to address the challenges associated with traditional drug formulations and paving the way for innovative therapeutic solutions. CD Bioparticles is dedicated to developing innovative products and services that help researchers advance drug delivery. The addition of these new polymers further demonstrates CD Bioparticles’ commitment to helping researchers develop new and effective therapeutic solutions.

CD Bioparticles provides a range of Low PDI polymers to tackle different drug delivery hurdles. They can improve drug absorption by increasing water solubility, protect drugs from degradation, and target them to specific sites. Additionally, these polymers allow controlled drug release and even co-delivery of multiple drugs within a single carrier, ultimately leading to more effective treatments with fewer side effects and improved patient convenience.

CD Bioparticles offers a wide variety of Polystyrene Family polymers to meet the needs of its customers. To learn more about new polymers and other products from CD Bioparticles, please visit https://www.cd-bioparticles.net/polystyrene-family.

About CD Bioparticles

CD Bioparticles is an established drug delivery company that provides customized solutions for developing and manufacturing novel biocompatible drug delivery systems. It specializes in various formulation and drug delivery technologies, from conventional liposomes and PEGylated liposomes to polymer microspheres and nanoparticles for drug delivery. The company also provides contract research services for drug delivery formulation, formulation feasibility study, process development and scale-up, as well as analytical and non-clinical research services.

Organisation Profile:
CD Bioparticles is an established drug delivery company which provides customized solutions for developing and producing new, biocompatible drug delivery systems.